Microbiomes have been discovered to play a role in inflammatory bowel disease (IBD), allergies, and immune-oncology, among others. The microbiome has become an attractive target for potential therapeutics, owing to its extensive role in gastrointestinal and non-gastrointestinal diseases. However, there are challenges associated with microbiome research. Determining the cause-effect relationships and designing microbiome-based therapies that can attain effective results on human health and microbial community are among such challenges. Recently, according to the research carried by the University of California (UC), San Diego, the microbiomes present in the gut were established to be connected to the level of active vitamin D in a person.
Another prospective study conducted by Albert Einstein College of Medicine assistant professor, H. Dean Hosgood, PhD, and other researchers from the U.S. and China highlights that the presence of certain species of bacteria is related to the heightened risk of lung cancer.
The global microbiome therapeutics market has witnessed significant growth owing to the increasing demand for therapeutic microbiomes imparting lesser side effects compared with the pre-existing standard of care. According to the market intelligence published by BIS Research, the global microbiome therapeutics market was estimated at $353.9 million in 2019 and is projected to grow at a CAGR of 25.64% during the forecast period, 2019-2030.
Currently, there are more than 111 novel microbiome therapeutics under development for a variety of target therapy specialties. The therapies represent the interpretation of basic scientific insights into innovative new treatment choices for patients. These 111 therapeutics are in various phases of clinical trials.
Various therapeutics ranging from fecal microbiota transplant to monoclonal microbials and other live bacterial consortia are being development for various diseases. The understanding regarding microbiome therapeutics has improved, and the strong investment from venture investors and pharmaceutical companies into the emerging microbiome firms that are pioneering work has made it possible for the field to move forward quickly.
The market growth at present is driven by the significant level of external funding received for executing research and therapeutic innovation, along with the increasing adoption of inorganic growth strategies in the market. In addition, there are further opportunities that can boost the growth of the market, including the entry of major players for the development of microbiome therapeutics and the growing eminence of microbiome therapeutics in cancer treatment.
Moreover, the potential of the global microbiome therapeutics market with respect to different regions, namely North America, Europe, Asia-Pacific (APAC), Latin America, and Rest-of-the-World, has been highlighted in the report. APAC is expected to dominate the global microbiome therapeutics market in 2020, with an overall contribution of 39.7% of the total market size. Increasing healthcare expenditure, coupled with existing government initiatives, is among the leading factors contributing to the growth of the market. Further, technological advancements in the infrastructure and strong investments in the microbiome sector are significantly promoting the growth of the microbiome therapeutics market in the APAC healthcare industry.
